The latest update is out from Cullinan Management (CGEM).
David Meek has been appointed as a Class I director and to the Audit Committee of a company, with his directorship taking effect on May 15, 2024. Bringing a wealth of experience from various leadership roles in the biotech and pharmaceutical industries, including CEO positions at Mirati Therapeutics and Ipsen S.A., Meek’s qualifications are expected to greatly benefit the company. As part of his non-employee director compensation, he will receive stock options and cash retainers. His appointment coincides with the announcement that Thomas Ebeling will resign from the board on June 26, 2024, after completing his term without any conflicts with the company.
Learn more about CGEM stock on TipRanks’ Stock Analysis page.
